Authors
Ruth Salim, Jennifer Bøgh Jørgensen, Anders Maagaard Lyhne, Katrin Bamdeg-Hvolbek, Per Ishøy Nielsen, Uffe Klausen, Peter Brown, Josée M Zijlstra, Lars Møller Pedersen, Mikkel Runason Simonsen, Mette Dahl, Tarec Christoffer El-Galaly, Kirsten Grønbæk
Published in
Hematological oncology. Volume 44. Issue 6.
Abstract
The optimal duration of follow-up for patients with follicular lymphoma (FL) eligible for initial watch-and-wait (WAW) remains undefined. We investigated the clinical characteristics and treatment trajectory patterns in patients with FL managed by initial, continuous WAW for at least 5 years (WAW5). Patients were identified from The Danish National Lymphoma Registry and detailed information was collected from health care records. Among the 393 included WAW5-patients, 271 (69%) were still untreated after a median follow-up of 5.3 years (after WAW5-timepoint). The 2-, 5-, and 10-year cumulative incidences of treatment initiation were 16% (95% CI 12%-20%), 28% (95% CI 24%-33%) and 38% (95% CI 32%-44%), respectively. In patients with stage II-IV disease, the best subset selection method in the training cohort (7:3 random sampling) identified the multivariable Cox regression model with number of nodal areas and bone marrow involvement with the best prognostic fit for time to treatment (TTT). Based on this, the WAW5-TTT risk score was constructed. The 5-year cumulative incidence of treatment initiation in the training cohort was 46% (95% CI 35%-58%), 37% (95% CI 26%-48%), and 13% (95% CI 5%-21%) in the high-, intermediate, and low-risk WAW5-TTT groups, respectively (Gray's test p < 0.0001). Results were confirmed in the test cohort. In conclusion, most patients remained treatment-free beyond the WAW5-timepoint. The findings support consideration of discontinuation of routine follow-up or transition to a more flexible, need-driven follow-up after WAW5, with the option of incorporating relevant risk factors to support individualized decision-making.
PMID:
43061793
Bibliographic data and abstract were imported from PubMed on 20 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0